NCL has created a focus group on LinkedIn, designed to connect researchers within the nanotech field. The aim of the group will be to discuss the latest news, trends, and...
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
The NCL has recently published a review article entitled “Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer” in Nature Reviews Clinical...
- 1 of 2
- next ›
Meet Us @
The 2017 SOT Annual Meeting and Tox Expo will be held in Baltimore, MD. Several staff members from the NCL will be attending, including Dr. Stephan Stern, NCL’s Pharmacology...
The United States Pharmacopeia (USP), along with co-sponsors AAPS and FIP, is hosting a three-day workshop on the technical and regulatory perspectives of nanomedicines. The...
The 2017 International Advanced Drug Delivery Symposium (IADDS) will be held in Taipei, Taiwan, April 6-7, 2017. NCL’s Sr. Principal Scientist in Immunology will be speaking....
- 1 of 2
- next ›